Welcome to our dedicated page for Mobix Labs SEC filings (Ticker: MOBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mobix Labs, Inc. (MOBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a fabless semiconductor and connectivity issuer listed on The Nasdaq Capital Market. Through these documents, investors can review how Mobix Labs reports on its RF, connectivity, interconnect and EMI filtering business, its capital structure and its financing activities.
Current and periodic reports such as Form 8‑K detail material events, including at‑the‑market offering agreements, warrant exercise inducement transactions, debt and equity financings, Nasdaq minimum bid‑price notices and extensions, and amendments to outstanding warrants that affect classification of these instruments as equity or liabilities. Certain 8‑K and 8‑K/A filings also describe leadership changes and advisory roles, as well as legal proceedings related to alleged failures to fund agreed‑upon investments.
Registration statements on Form S‑1 and Form S‑3, along with their amendments, outline registered offerings of Mobix Labs’ Class A common stock and the use of proceeds the company identifies, such as working capital, general corporate purposes, growth initiatives and M&A strategy. These filings also provide background on the company’s fabless semiconductor model, RF and connectivity focus, and risk factors.
Annual and quarterly reports on Forms 10‑K and 10‑Q, when filed, give a broader view of Mobix Labs’ financial condition, including revenue, gross margin, operating loss and liquidity metrics, as well as segment and market discussions. Preliminary, unaudited financial information referenced in news releases is later finalized in these periodic reports.
On Stock Titan, Mobix Labs filings are updated in near real time from EDGAR. AI‑powered summaries help explain complex sections of 10‑K and 10‑Q reports, highlight key points from 8‑K disclosures, and make it easier to interpret warrant, debt and equity terms. Users can also review ownership and insider‑related information when available through Forms 3, 4 and 5 to understand equity incentives and changes in beneficial holdings.
Mobix Labs, Inc. (MOBX) filed an amended Form S-1 registering the resale of up to 12,890,274 shares of Class A common stock by selling stockholders. The company is not selling any shares in this offering and will not receive proceeds from stockholder sales.
If outstanding warrants covered by this prospectus are exercised for cash, Mobix Labs states it would receive approximately $9.8 million in gross proceeds. The filing notes the registered shares would equal about 18% of outstanding Class A shares as of September 4, 2025, and that resales—or the perception of them—could pressure the trading price.
The prospectus also highlights recent financing activities. On September 3, 2025, a holder exercised 5,486,467 warrants for cash at $0.8202 per share, generating ~$4.5 million in gross proceeds, and received new inducement warrants for 8,229,701 shares at $1.08. On August 13, 2025, the company issued a $550,000 senior secured note convertible at $0.70 (up to 2,500,000 shares), with 150,000 commitment shares and caps including a 4.99% beneficial ownership limit and an exchange cap of 5,747,105 shares.
Bill Carpou, a director of MOBIX LABS, INC. (MOBX), reported equity changes dated 09/23/2025. The filing shows a grant of 46,855 Restricted Stock Units (RSUs) to the reporting person, increasing his direct beneficial ownership to 299,022 Class A common shares after the transaction. The report also discloses two fully vested stock options: one with an exercise price of $4.18 covering 20,000 shares (expiring 08/10/2030) and another with an exercise price of $6.84 covering 133,416 shares (expiring 04/04/2032). The form was signed on behalf of the reporting person by an attorney-in-fact on 09/25/2025.
Frederick C. Goerner, a director of Mobix Labs, Inc. (MOBX), reported multiple equity awards and holdings. On 09/23/2025 he was granted 46,855 Restricted Stock Units (RSUs) with a reported price of $0, bringing his reported beneficial ownership to 1,483,380 shares of Class A Common Stock (direct). The filing also shows fully vested, exercisable options to purchase 20,000 shares at $4.18 and 133,416 shares at $6.84. Additionally, the report lists 217,391 shares of Class B Common Stock convertible into Class A Common Stock; conversion occurs at the Reporting Person's option and will be automatic upon certain transfers or upon the first trading day after the seventh anniversary of the Closing Date. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
Kurt Busch, a director of Mobix Labs, Inc. (MOBX), reported awards and existing holdings on a Form 4 dated with transactions on 09/23/2025. The filing shows 46,855 restricted stock units (RSUs) were granted to Mr. Busch on 09/23/2025, increasing his beneficial ownership to 372,429 shares of Class A common stock.
The report also lists two fully vested, exercisable stock options held directly by Mr. Busch: an option to buy 20,000 shares at an exercise price of $4.18 (expiration 08/10/2030) and an option to buy 133,416 shares at $6.84 (expiration 04/04/2032). The Form 4 was signed by an attorney-in-fact, Terri Aprati, on 09/25/2025.
Mobix Labs insider report: Director David J. Aldrich received 46,855 Restricted Stock Units on September 23, 2025 that will vest on October 1, 2025, and acquired the RSUs at no cash cost. Following that grant, he beneficially owns 289,744 shares of Class A common stock.
Derivative holdings: The filing discloses two fully vested, exercisable stock options: 20,000 options with a $4.18 exercise price (expiring 08/10/2030) and 133,416 options with a $6.84 exercise price (expiring 04/04/2032). The form was signed by an attorney-in-fact on September 25, 2025.
Mobix Labs insider ownership and awards disclosed in Schedule 13D. Keyvan Samini and related trusts report beneficial ownership of 3,316,733 shares of Class A common stock (including 125,000 Class B shares convertible into Class A), representing 5.6% of voting power based on the stated share counts. The filing describes acquisition of Class A shares, options and a grant of 2,550,000 restricted stock awards to Samini on May 5, 2025, which vest over two years and may accelerate at certain stock-price thresholds. Samini is President, CFO and a director of the issuer; employment agreements and multiple equity awards and RSUs are summarized and incorporated by reference.
MOBIX LABS, INC. director Bill Carpou reported a sale of 19,953 shares of Class A common stock on 09/12/2025 at an average price of approximately $0.9418 per share, reducing his direct holdings to 252,167 shares. The filing also shows two fully vested options: one exercisable at $4.18 per share covering 20,000 underlying shares (expires 08/10/2030) and another at $6.84 covering 133,416 shares (expires 04/04/2032). The report was signed by an attorney-in-fact on 09/16/2025 and includes an explanation that sale prices ranged from $0.9418 to $0.9419 and that option grants are fully vested and exercisable.
MOBIX Labs, Inc. (MOBX) filed an S-1 that discloses its post-merger financial position, material financing transactions and near-term liquidity risk. The company completed a business combination and began trading on Nasdaq under MOBX and MOBXW, received a $19,750 PIPE at $10.00 per share and raised net proceeds of $3,645 in an April 2025 offering. For the nine months ended June 30, 2025 the condensed statements show a net loss of $30,402 and an accumulated deficit of $134,859. Management states there is substantial doubt about going concern, citing inadequate liquidity beyond ~ninety days and the need for additional debt or equity financing.
Mobix Labs, Inc. entered into a warrant exercise inducement agreement under which a warrant holder agreed to exercise Existing Warrants for cash to purchase up to 5,486,467 shares of common stock at $0.8202 per share, and in return will receive new Inducement Warrants to buy up to 8,229,701 additional shares.
The company expects aggregate gross proceeds of approximately $4.5 million from these cash exercises. It will pay Roth Capital Partners a 7.0% cash fee on the proceeds and issue Roth Placement Agent Warrants to purchase up to 384,053 shares at $1.08 per share. The Inducement Warrants will have a $1.08 exercise price, become exercisable upon stockholder approval, and remain exercisable for five years.
The Inducement Warrants include 4.99% and 9.99% ownership caps, cashless exercise if no effective registration is available, and Black Scholes-based cash redemption rights in certain fundamental transactions. Mobix agreed to seek stockholder approval within 60 days after the closing date and to limit new issuances and registrations for 45 days, and it extended the termination date of certain unexercised Series B warrants to April 3, 2030.
Mobix Labs, Inc. reported several financing deals that add short-term funding but also introduce potential dilution and collateral pledges. The company issued a secured promissory note to Lendspark Corporation for
Through a separate Business Loan and Security Agreement with Maximcash Solutions LLC, Mobix received